title: CD5-expressing B-cell lymphomas/leukemias: relatively high frequency of CD5+ B-cell lymphomas with an overall poor prognosis in Nagasaki Japan.
abstract: To characterize CD5+ B-cell neoplasms in Japan, where chronic lymphocytic leukemia (CLL) is rare and of different subtypes in comparison with Western countries, we collected 58 cases of CD5+ B-cell lymphomas/leukemias and analyzed their clinicopathologic features. According to the French-American-British (FAB) and standard histologic classification, the cases corresponded to small lymphocytic lymphoma (SLL, group I; n = 22, consisting of CLL, n = 10, CLL/PL, n = 3, and CLLmixed, n = 7); intermediate differentiated lymphoma/mantle cell lymphoma (IDL/MCL, group II, n = 18); and others with CD5-positive lymphomas (group III, n = 18). The CD5+ B-cell lymphomas showed morphologic and prognostic variability among the three groups. The clinical and immunophenotypic features were remarkably consistent in leukemic disease being seen in 73% of all cases, splenomegaly in 63%, and intense CD19, CD20, surface membrane immunogobulin M (SmIgM) or SmIgM and SmIgD, light-chain expression, and no CD10 expression. The median survival time of groups I, II, and III was 7.8, 3.3, and 0.8 years, respectively. These findings suggest that CD5 antigens may serve as valid markers for the prognosis and clinical features of B-cell lymphomas and that CD5+ B-cell lymphomas with an overall poor prognosis occurs at a relatively high frequency in Japan. This also suggests that a combination of immunophenotypic and morphologic features is of value for characterizing CD5+ B-cell neoplasms.
authors.affiliation: Department of Laboratory Medicine, Nagasaki University School of Medicine, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kamihira
authors.forename: Y
authors.initials: Y
authors.lastname: Hirakata
authors.forename: S
authors.initials: S
authors.lastname: Atogami
authors.forename: H
authors.initials: H
authors.lastname: Sohda
authors.forename: K
authors.initials: K
authors.lastname: Tsuruda
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
authors.forename: M
authors.initials: M
authors.lastname: Tomonaga
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis; D001772:Blood Cell Count; D018956:CD5 Antigens / Q000032:analysis*; D005260:Female; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D016130:Immunophenotyping; D007564:Japan / Q000453:epidemiology; D015448:Leukemia, B-Cell / Q000145:classification / Q000453:epidemiology* / Q000473:pathology; D015993:Life Tables; D016393:Lymphoma, B-Cell / Q000145:classification / Q000453:epidemiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis; D011379:Prognosis; D012189:Retrospective Studies; D013163:Splenomegaly / Q000209:etiology; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D015703:Antigens, CD; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018956:CD5 Antigens; D007147:Immunoglobulin Light Chains; D007075:Immunoglobulin M; D009363:Neoplasm Proteins